Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

摘要: Purpose: To identify microRNAs (miRNA) that predict response to anti-EGFR antibodies in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Experimental Design: miRNA profiling was performed a training set of 87 mCRC refractory chemotherapy treated antibodies. This included 33 fresh-frozen (FF) and 35 formalin-fixed paraffin-embedded (FFPE) samples retrospectively collected 19 prospectively FF samples. An independent validation cohort consisting 26 FFPE from used confirm our findings. Results: After screening the expression 1,145 miRNAs set, we identified hsa-miR-31-3p level significantly associated progression-free survival (PFS). Statistical models based on discriminated between high low risk progression for both These were confirmed [HR, 4.1; 95% confidence interval (CI), 1.1–15.3; P = 0.028). The percentage variation RECIST criteria series ( r 2 0.49; 0.0035) status determined by 0.02, Kruskal–Wallis rank test). Nomograms built validated PFS-depending level. Following vitro studies, 47 genes regulated hsa-miR-31-3p. Conclusion: Hsa-miR-31-3p seems be new biomarker whose allows identification who are more likely respond therapy. Clin Cancer Res; 20(12); 3338–47. ©2014 AACR .